About: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 2003

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2003 (uk) im Juni 2003 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 2003 (ast) scientific article published on 01 June 2003 (en)
publication date	wds:Q73566543-95501213-8BC5-405F-AE73-4C0A63610DAA
publication date	2003-06-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q73566543-2AB235E7-E114-4CB6-A593-D3A9A2184092 wds:Q73566543-2BE0F5D0-52A6-4EC5-946A-17C0C1D3488B wds:Q73566543-35DF4D1D-790D-402E-842D-92E47F6C9A92 wds:Q73566543-3815344A-DB92-4A00-8C86-A62F1F94FD45 wds:Q73566543-38F8675E-4F1D-4C7C-BAE0-07DBD763F618 wds:Q73566543-58D8E986-C78D-4DC4-9596-5440FFCA9657 wds:Q73566543-A0D7D383-0F71-4762-96D7-C8C3B18C68C3 wds:Q73566543-A14606ED-D8C7-4CD1-9AFF-5795C8D05D8D wds:Q73566543-AEE9FFEC-ACB4-4267-95E5-284DEFD4C1F0 wds:Q73566543-AF5ABF3A-4F5D-48DE-BB83-EFD226B42E7D wds:Q73566543-D13D609A-B5B4-4558-B2B7-321FF72DAB93 wds:Q73566543-D3CB71F1-A36C-4040-9AF5-171D28BBE1EB wds:Q73566543-DD5D32D8-D3C8-44E7-A8C6-E83150BA7E6A wds:Q73566543-FCF81344-8DF6-49AC-AB2E-223657873B12
cites work	Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin Barrett's esophagus: age, prevalence, and extent of columnar epithelium Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication A comparison of five maintenance therapies for reflux esophagitis Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor Treatment of Helicobacter pylori infection Nonprescription H2-receptor antagonists.
author name string	wds:Q73566543-0A18FEBC-8923-4A9E-B5D5-91D2F6BC66B7 wds:Q73566543-57321FCB-647E-4465-B678-0DB8F9086366 wds:Q73566543-88976FBD-5E35-4851-AFC0-8BA205313DCC wds:Q73566543-A008CEC8-09C4-4C7D-B072-0650FD64E1B7 wds:Q73566543-B97D77C7-9532-421C-A07E-0800B2C36A0D
author name string	D C Mays P P Kammer L J Egan R A Dierkhising G M Myhre
rdfs:label	CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms (en) CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms (nl)
skos:prefLabel	CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms (en) CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms (nl)
name	CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms (en) CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms (nl)
author	wds:Q73566543-6478233F-1DD2-4E4F-933C-36888B9E0381
author	Joseph A Murray
title	wds:Q73566543-FE7E9322-0AE5-41A0-AFAD-C14C8AB5FFA1
title	CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms (en)
page(s)	wds:Q73566543-5B49EEF2-AE6E-45EE-887D-1D4C9C197AF6
page(s)	1521-1528
instance of	wds:Q73566543-A9DDBEFF-DACA-4F9D-9141-00A6CF3F3B29
instance of	scholarly article
PubMed ID	wds:Q73566543-4E70E0ED-07C2-4FF3-803F-98B31A63CA8F
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12823155
PubMed ID	12823155
published in	wds:Q73566543-0741D2CD-87B5-442C-A7D3-3025FA7200A3
published in	Alimentary Pharmacology & Therapeutics
issue	wds:Q73566543-90BDA509-8D6C-46DA-B4FC-C16555100D6E
volume	wds:Q73566543-97BB2677-6F38-4CB6-ABB9-9CBB3998CA64
issue	12
volume	17
DOI	wds:Q73566543-740142C4-A1A1-4809-A00C-1F6025A3C7A7
DOI	http://dx.doi.org/10.1046/J.1365-2036.2003.01645.X
DOI	10.1046/J.1365-2036.2003.01645.X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73566543
is cites work of	Proton pump inhibitors: an update of their clinical use and pharmacokinetics Refractory GERD: what is it? Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure Effect of CYP2C192 and 17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases. Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing The role of pharmacogenetics in nonmalignant gastrointestinal diseases Do proton pump inhibitors contribute to weight gain? Heartburn refractory to proton-pump inhibitors
is cites work of	wds:Q36895523-E2CB1393-FA04-4436-A734-9EC77BC27994 wds:Q36729180-508A58BD-1F60-487B-B31C-17D045403A5F wds:Q46748222-217875BE-6D58-479A-8EB1-64BD93F97B80 wds:Q87139414-F1B22D83-0699-4866-8E6F-3193B6E1E21F wds:Q37235086-2C4A3F1C-4DCD-4FEC-8124-5EC93574F2F7 wds:Q37981892-6DBBFE0C-FF5B-40C5-88CB-2DCE293083E1 wds:Q34594205-A039921A-750D-45C3-87FF-53FAF3F0F7B4 wds:Q38029235-E091A851-D4A5-4B95-9F4D-090B055CD0E1 wds:Q79770413-38BA489C-29B1-4C95-A9D6-BCA4EF4D57C1

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 194 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software